E. Cartwright
Royal Marsden Hospital · 11 works · 28 citations · h-index 3
Top works
- 443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding
- Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE
- Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?
- EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers
- 1253P Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa results of the WAKING trial
- 405P DKN-01 and atezolizumab as second or third-line therapy in advanced mismatch repair proficient (MMRp) oesophagogastric adenocarcinoma (OGA): WAKING trial
- Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study
- 477TiP A randomised phase II study of zimberelimab ± domvanalimab immunotherapy in resectable mismatch repair deficient (dMMR) gastric and gastroesophageal junctional (G/GOJ) adenocarcinoma (ZODIAC)
- DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial
- PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma
- 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience